Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Replacement Astrazeneca Plc

28 May 2014 11:48

RNS Number : 2308I
Morgan Stanley Securities Limited
28 May 2014
 



AMENDMENT

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Securities Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

22 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 USD 0.25 ORDINARY

 PURCHASES

 2,874,592

 44.0200 GBP

 42.2950 GBP

 USD 0.25 ORDINARY

 SALES

 2,225,951

 44.0200 GBP

 42.3000 GBP

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 USD 0.25 ORDINARY

 CFD

 LONG

 20

 54.2200 EUR

 USD 0.25 ORDINARY

 CFD

 SHORT

 20

 53.6600 EUR

 USD 0.25 ORDINARY

 CFD

 LONG

 2,889

 42.7500 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 18,108

 42.7500 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 767

 43.0708 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 20

 43.1165 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 3,300

 43.1426 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 1,350

 43.1473 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 300

 43.1531 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 316

 43.2234 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 3,983

 43.2286 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 8,178

 43.2286 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 1,772

 43.2286 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 13,750

 43.2341 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 33,695

 43.2545 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 6,500

 43.2626 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 3,304

 43.2657 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 548,364

 43.3108 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 25,000

 43.3136 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 88

 43.4000 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 124,501

 43.4658 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 22,500

 43.5342 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 3,452

 43.6001 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 12,401

 43.6001 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 5,695

 42.7500 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 786

 42.7500 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 164

 42.7500 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 316

 42.7500 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 31,833

 42.7500 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 3,000

 42.7842 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 392

 42.9129 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 554

 43.0220 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 3,286

 43.0408 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 7,222

 43.2368 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 320

 43.2368 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,602

 43.2368 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 12,401

 43.2574 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 37,302

 43.2574 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 100,000

 43.2864 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 176

 43.2900 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 543,366

 43.2947 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 100,000

 43.3000 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 27

 43.3000 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 2,000

 43.3249 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 88,251

 43.3352 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 68,828

 43.3352 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 52,290

 43.3352 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 25,020

 43.3352 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 33,030

 43.3352 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 5,676

 43.3414 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 5,120

 43.3497 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 29,273

 43.3564 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 122,001

 43.3616 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,844

 43.3758 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 4,871

 43.3832 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 2,000

 43.3883 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 88

 43.3950 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 25,000

 43.5121 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 33,695

 43.5176 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 10,000

 43.5648 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 8,900

 43.5648 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 5,000

 43.5648 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,100

 43.5648 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 22,500

 43.5800 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 4,000

 43.6397 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 685

 43.7039 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 766

 43.7039 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,382

 43.7039 GBP

 USD 0.25 ORDINARY

 CFD

 SHORT

 2,230

 43.7039 GBP

 USD 0.25 ORDINARY

 CFD

 LONG

 378

 481.3097 SEK

 USD 0.25 ORDINARY

 CFD

 LONG

 805

 481.4103 SEK

 USD 0.25 ORDINARY

 CFD

 LONG

 1,000

 482.2000 SEK

 USD 0.25 ORDINARY

 CFD

 SHORT

 1,000

 482.1000 SEK

 USD 0.25 ORDINARY

 CFD

 LONG

 1,204

 43.1566 GBP

 ADRS

 CFD

LONG

 300.00 (Traded in ADR form)

 71.9633 USD

 ADRS

 CFD

LONG

 4,846.00 (Traded in ADR form)

 72.1600 USD

 ADRS

 CFD

LONG

 795.00 (Traded in ADR form)

 72.1600 USD

 ADRS

 CFD

LONG

 403.00 (Traded in ADR form)

 73.1500 USD

 ADRS

 CFD

LONG

 2,457.00 (Traded in ADR form)

 73.1500 USD

 ADRS

 CFD

SHORT

 300.00 (Traded in ADR form)

 72.1200 USD

 ADRS

 CFD

SHORT

 2,367.00 (Traded in ADR form)

 72.1600 USD

 ADRS

 CFD

SHORT

 389.00 (Traded in ADR form)

 72.1600 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

28 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERLLFSIELITFIS
Date   Source Headline
21st Aug 20197:00 amRNSUpdate on the Phase III NEPTUNE trial
20th Aug 20197:00 amRNSFarxiga met primary endpoint in landmark Phase III
19th Aug 20197:00 amRNSDirectorate Change
14th Aug 20197:00 amRNSLynparza Phase III PAOLA-1 trial met primary endpo
14th Aug 20197:00 amRNSCalquence granted US Breakthrough Therapy Designat
9th Aug 20199:28 amRNSAmendment: Tagrisso significantly improves overall
9th Aug 20197:00 amRNSTagrisso significantly improves overall survival
7th Aug 20197:00 amRNSLynparza Phase III PROfound trial in HRR*
5th Aug 20197:00 amRNSForxiga label updated in the EU in type-2 diabetes
1st Aug 20193:00 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSAZN: H1 2019 Results
15th Jul 20197:00 amRNSUpdate on US regulatory decision for Farxiga
12th Jul 20197:00 amRNSImfinzi granted US Orphan Drug Designation for
1st Jul 20193:00 pmRNSTotal Voting Rights
1st Jul 20197:00 amRNSForxiga receives positive EU CHMP opinion for
1st Jul 20197:00 amRNSFasenra receives positive EU CHMP opinion for self
27th Jun 20197:00 amRNSImfinzi improves overall survival at interim
19th Jun 20197:00 amRNSBreztri Aerosphere (PT010) approved in Japan for
19th Jun 20197:00 amRNSLynparza approved in Japan for 1st-line
19th Jun 20197:00 amRNSBevespi Aerosphere approved by the Japanese
18th Jun 20197:00 amRNSLynparza approved in the EU for 1st-line
17th Jun 20197:00 amRNSCalquence significantly prolonged the time patient
12th Jun 20194:45 pmRNSPublication of a Prospectus
6th Jun 20197:00 amRNSCalquence Phase III ELEVATE-TN trial met primary
5th Jun 201912:36 pmEQSHardman & Co Research: AstraZeneca: Where has all the cash gone?
3rd Jun 20193:00 pmRNSBlock listing Interim Review
3rd Jun 20193:00 pmRNSTotal Voting Rights
3rd Jun 20197:00 amRNSLynparza nearly doubled time patients lived with
10th May 20197:00 amRNSPooled analyses of the roxadustat global Phase III
8th May 20192:00 pmRNSDirector/PDMR Shareholding
8th May 201911:00 amRNSDirector Declaration
8th May 20197:00 amRNSTrastuzumab deruxtecan demonstrated clinically
7th May 20197:00 amRNSCalquence PhIII ASCEND trial met primary endpoint
3rd May 20197:00 amRNSQternmet XR approved in the US for type-2 diabetes
1st May 20193:00 pmRNSTotal Voting Rights
1st May 201912:00 pmRNSDirector/PDMR Shareholding
29th Apr 20197:00 amRNSLynparza receives positive EU CHMP opinion for 1st
26th Apr 20195:45 pmRNSResult of AGM
26th Apr 20197:00 amRNSAZN: Q1 2019 Results
10th Apr 20197:00 amRNSLynparza approved in EU for the treatment of germl
9th Apr 20194:10 pmEQSHardman & Co Research: Global Pharmaceuticals: 2018 industry sales
4th Apr 20191:30 pmRNSHolding(s) in Company
3rd Apr 201910:00 amRNSDirector/PDMR Shareholding
2nd Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20196:00 pmRNSAstrazeneca
1st Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20197:00 amRNSSelumetinib gets Breakthrough Therapy Designation
29th Mar 20195:15 pmRNSResults of Placing
29th Mar 20197:00 amRNSProposed placing of new ordinary shares
29th Mar 20197:00 amRNSAZ and Daiichi Sankyo enter collaboration in novel

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.